RoosterBio has entered an exclusive distributor partnership with MineBio Life Sciences to expand access to scalable, research-grade and current good manufacturing practice (cGMP)-grade mesenchymal stem cell (MSC) and exosome bioprocessing solutions across China.
Halozyme Therapeutics’ subsidiary Halozyme Hypercon has signed a global exclusive partnership and licence agreement with Vertex Pharmaceuticals for the former’s Hypercon technology.
Apnimed has signed a senior secured credit facility of up to $150m with funds managed by HealthCare Royalty Partners (HCRx) to support the planned launch of AD109.
Neurocrine Biosciences has signed a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, which represents $2.9bn in total transaction equity value.
Aspect Biosystems has secured a C$79m($56.6m) investment from the Government of Canada to support a C$280m multi-year project aimed at advancing its pipeline of bioengineered cellular medicines for endocrine and metabolic diseases.
Germany-based Merck KGaA (Merck) has completed its previously announced acquisition of the chromatography business of JSR Life Sciences.
Biocytogen has entered a strategic partnership with Sihuan Pharmaceutical to advance new therapeutics across several disease areas, including weight loss.
Symeres has entered a collaboration with Ambagon Therapeutics on molecular glue research in colorectal cancer, aiming to address diseases considered difficult to treat.
Teva Pharmaceutical has announced the US Food and Drug Administration (FDA) approval for Ponlimsi (denosumab-adet) as a biosimilar to Prolia, alongside the acceptance of its biosimilar candidate applications for Xolair (omalizumab) by both the agency and the European Medicines Agency (EMA).
uBriGene Biosciences has signed a strategic partnership with Cellinfinity BIO to advance the clinical development of in vivo chimeric antigen receptor T-cell (CAR-T) therapy programmes for haematologic and solid tumours.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.